New Cohort Study to Spinraza in Adult Spinal Muscular Atrophy (SAS)

Late last year 2018, launch Biogen a new cohort study.
SPINRAZA in Adult Spinal Muscular Atrophy type 2 and 3 in age 18-70 , which is currently recruiting participants in the US and is targeting additional results.
The study will evaluate the safety, tolerability and effectiveness of SPINRAZA in adults with SMA.

In Germany adults are treated with Spinraza aswell and With positive results.

Clinical Trials
NCT03709784
Spinraza in Adult Spinal Muscular Atrophy (SAS)

#study #adults #treatment #Spinraza

Publicerat av

Liz

Att acceptera vad som händer och låt trollen i ljuset, kanske du borde att tro mer på dig själv Liz Photopage Instagram

3 reaktioner till “New Cohort Study to Spinraza in Adult Spinal Muscular Atrophy (SAS)”

Kommentarer inaktiverade.